Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 16, 2023, Selecta Biosciences, Inc. (the "Company") held its 2023 Annual Meeting of Stockholders. A total of 102,390,960 shares of the Company's common stock, par value $0.0001 per share (the "common stock"), were present electronically or represented by proxy at the meeting, representing approximately 66.74% of the Company's outstanding common stock as of the April 17, 2023 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2023, as supplemented on June 13, 2023.




Proposal 1 - Election of three Class I Directors to serve until the 2026 Annual
Meeting of Stockholders, and until their respective successors have been duly
elected and qualified.
NOMINEE                        Votes FOR    Votes WITHHELD     Broker Non-Votes
Scott D. Myers                 57,117,703     12,779,024          32,494,233
Timothy A. Springer, Ph.D.     60,365,992      9,530,735          32,494,233
Patrick Zenner                 59,798,777     10,097,950          32,494,233

Based on the votes set forth above, each director nominee was duly elected to serve until the Company's 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

Proposal 2 - Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company's named executive officers.

Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes

63,731,591 5,090,940 1,074,196 32,494,233

Based on the votes set forth above, the stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of our named executive officers.

Proposal 3 - Approval of an amendment to the Company's Restated Certificate of Incorporation, as amended, to change the vote required for stockholders to approve an amendment to the Company's Amended and Restated Bylaws from two-thirds to a majority of the outstanding shares of capital stock of the Company entitled to vote thereon.


 Votes FOR     Votes AGAINST    Votes ABSTAINED    Broker Non-Votes
 67,852,901      1,742,501          301,325           32,494,233

The proportion of outstanding shares voting in favor of the amendment to the Company's Restated Certificate of Incorporation, as amended, was less than two-thirds of the outstanding shares of capital stock of the Company entitled to vote thereon. Based on the results of this proposal, the stockholders did not approve the amendment to the Company's Restated Certificate of Incorporation, as amended, to change the vote required for stockholders to approve an amendment to the Company's Amended and Restated Bylaws from two-thirds to a majority of the outstanding shares of capital stock of the Company entitled to vote thereon.

Proposal 4 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.


  Votes FOR     Votes AGAINST    Votes ABSTAINED    Broker Non-Votes
 101,433,021       923,103           34,836                -

Based on the votes set forth above, the stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses